Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3149408

Cl.c1ccc2c(C3CNCCN3)nsc2c1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 1/20 0.33
DRD4 known ✓ P21917 1/20 0.33
DRD3 known ✓ P35462 1/20 0.33
PARP1 known ✓ P09874 1/20 0.32
ACHE known ✓ P22303 1/20 0.32
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EPAS1 Q99814 5/20 0.33
GRM2 Q14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978037 0.98 KDM4E (0.42) KDM4EMAPTALDH1A1HSD17B10EPAS1
Hydrochloric Acid SCHEMBL4442743 0.77 KDM4E (0.35) KDM4EMAPTPARP1
Hydrochloric Acid SCHEMBL1838069 0.74 KDM4E (0.51) KDM4EMAPTALDH1A1HSD17B10EPAS1
SCHEMBL2201319 0.73 KDM4E (0.41) KDM4EMAPTALDH1A1HSD17B10EPAS1
SCHEMBL4558894 0.73 HTR2A (0.44) KDM4EMAPTALDH1A1HSD17B10DRD2
SCHEMBL8469607 0.73 KDM4E (0.41) KDM4EALDH1A1PARP1
SCHEMBL1545124 0.72 KDM4E (0.49) KDM4EMAPTALDH1A1HSD17B10EPAS1
SCHEMBL9591123 0.70 GPR3 (0.35) ALDH1A1HSD17B10
SCHEMBL7993430 0.70 SLC6A4 (0.40) MAPTDRD2
SCHEMBL9274343 0.69 SSTR4 (0.36) DRD2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112724066-B Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof 海南鑫开源医药科技有限公司 2022-10-21 CN claimed
CN-112961150-A Impurities in ziprasidone hydrochloride and preparation method thereof 海南鑫开源医药科技有限公司 2021-06-15 CN claimed
CN-112920135-A Dimer impurity in ziprasidone hydrochloride raw material and preparation method thereof 海南鑫开源医药科技有限公司 2021-06-08 CN claimed
CN-112778298-A Impurities in ziprasidone hydrochloride and preparation method thereof 海南鑫开源医药科技有限公司 2021-05-11 CN claimed
CN-112778298-B Impurities in ziprasidone hydrochloride and preparation method thereof 海南鑫开源医药科技有限公司 2023-02-24 CN disclosed
CN-112724066-B Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof 海南鑫开源医药科技有限公司 2022-10-21 CN disclosed
CN-112961150-A Impurities in ziprasidone hydrochloride and preparation method thereof 海南鑫开源医药科技有限公司 2021-06-15 CN disclosed
CN-112920135-A Dimer impurity in ziprasidone hydrochloride raw material and preparation method thereof 海南鑫开源医药科技有限公司 2021-06-08 CN disclosed
CN-112778298-A Impurities in ziprasidone hydrochloride and preparation method thereof 海南鑫开源医药科技有限公司 2021-05-11 CN disclosed
CN-102250083-B Method for preparing ziprasidone QILU TIANHE PHARMACEUTICAL CO LTD 2013-09-04 CN disclosed
CN-102250083-A Method for preparing ziprasidone QILU TIANHE PHARMACEUTICAL CO LTD 2011-11-23 CN disclosed
US-20100081668-A1 POLYMORPHS OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF RICHTER GEDEON NYRT. (HU) 2010-04-01 US disclosed
US-5801186-A ANTIPSYCHOTIC AGENTS HOECHST MARION ROUSSEL, INC. (US) 1998-09-01 US disclosed
US-5371087-A Antipsychotic, analgesics, anticonvulsant and anxiolytic agent HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1994-12-06 US disclosed
US-5338846-A Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt PFIZER INC. (US) 1994-08-16 US disclosed
EP-0584903-A1 Process for preparing aryl piperazinyl-heterocyclic compounds PFIZER INC. (US) 1994-03-02 EP disclosed
US-5229388-A 3-[4-(1-substituted-4-piperazinyl)butyl]-4-thiazolidinone and related compounds HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-07-20 US disclosed
US-5136037-A 3-(4-substituted-4-piperazinyl)butyl-4-thiazolidinone and related compounds HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1992-08-04 US disclosed
US-5037984-A Anticonvulsants; anxiolytic agents HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1991-08-06 US disclosed
US-4933453-A ANTIPSYCHOTIC, ANALGESIC, ANTICONVULSANT, AND ANXIOLYTIC AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1990-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081668-A1 POLYMORPHS OF 5--6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF TPH1, TPH2, HTR1A DRD2 32/4885DRD4 22/4885DRD3 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.